“Alkaline water” fails to be an effective alternative for prevention of recurrent urinary stones

While the JP Mor­gan Health­care Con­fer­ence was full of voic­es of mea­sured op­ti­mism, root­ing for the mar­ket to bounce back in 2024, one long­time biotech

Celldex Ther­a­peu­tics has un­veiled 52-week re­sults from a mid-stage study of its an­ti-KIT drug in chron­ic hives, rais­ing an­tic­i­pa­tion for on­go­ing reg­is­tra­tional stud­ies. But the